- PharmaLogic Holdings has signed a definitive agreement to acquire Lantheus Holdings’ CDMO business and its radiopharmaceutical manufacturing facility in Springfield, New Jersey. Financial terms were not disclosed.
- The acquisition will expand PharmaLogic’s US manufacturing capacity for radiopharmaceutical therapeutics and includes a long-term supply agreement under which its Agilera business will manufacture lutetium Lu 177 dotatate for Lantheus.
PharmaLogic Holdings has signed a definitive agreement to acquire the CDMO business and radiopharmaceutical manufacturing facility operated by Lantheus Holdings in Springfield, New Jersey. The financial terms of the transaction were not disclosed. The deal is subject to regulatory review and other customary closing conditions, with both companies continuing to operate independently until completion.
The Springfield facility has experience in theranostic manufacturing, research and clinical development. Its employees will join Agilera, PharmaLogic’s therapeutic CDMO business, following the transaction. The agreement also includes a long-term supply arrangement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
The acquisition will expand PharmaLogic’s US capacity for radiopharmaceutical therapeutics and add to Agilera’s capabilities in radioligand therapies (RLTs). Agilera has more than 15 years of experience supporting RLT development and commercial launches and currently supplies an alpha therapy to more than 30 countries. PharmaLogic said the addition of the Springfield site will establish a transatlantic platform supporting RLT programs from early clinical development through commercial launch and global supply.
“The acquisition would strengthen Agilera’s radioligand therapy capabilities and expand its US manufacturing capacity.”
PharmaLogic CEO Etienne Montagut
“PharmaLogic’s radiopharmaceutical expertise and manufacturing capabilities made it a suitable long-term owner for the business and facility.”
Lantheus CEO Mary Anne Heino
